Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)

Trial Profile

A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crizanlizumab (Primary) ; Hydroxycarbamide
  • Indications Vaso-occlusive crisis
  • Focus Therapeutic Use
  • Acronyms STAND
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 30 Sep 2019 Planned End Date changed from 2 Dec 2027 to 5 Nov 2027.
    • 29 Jun 2019 Planned initiation date (Estimated date of first participant enrollement) changed from 29 Apr 2019 to 25 Jul 2019.
    • 29 Jun 2019 Planned End Date changed from 7 Sep 2027 to 2 Dec 2027.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top